Lobe Sciences Ltd. (CNSX: LOBE)
Health Care · Pharmaceuticals · CA
CA$0.07
-6.67% today · +40.0% 1Y
Lobe Sciences Ltd. (CNSX: LOBE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $16.92M and employs 5 people.
Over the last twelve months the share price has gained 40.0%, trading between 0.03 and 0.18.
Tweenvest scores Lobe Sciences Ltd. across four factors: quality 28/100. Its strongest factor is quality.
LOBE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $16.92M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- -0.06
- 52-week high
- CA$0.18
- 52-week low
- CA$0.03
- Avg volume (3M)
- —
- Shares outstanding
- 332.89M
- Employees
- 5
- Next earnings
- —
About Lobe Sciences Ltd.
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
- ISIN
- CA53946V2066
- Founded
- 2018
- Listed since
- Jun 28, 2012
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.